Merck vs Lilly: Who Is Winning the 2026 Pharma M&A Race?
Merck and Lilly Execute $13.4B Pharma Acquisition Strategy
Merck and Lilly announce acquisitions totaling $13.4 billion in 2026. The deals include Terns Pharma, Centessa Pharmaceuticals, Kelonia Therapeutics, and CrossBridge Bio. These acquisitions aim to bolster their oncology and biotechnology pipelines. Merck targets Terns Pharma for its chronic myeloid leukemia candidate, while Lilly focuses on expanding its biotechnology capabilities. The acquisitions fill critical gaps in their respective portfolios, enhancing their competitive positions in oncology and biotechnology. Terns Pharma Deal Centessa Pharmaceuticals Deal
Detailed Analysis of Merck and Lilly's 2026 Acquisitions
Merck acquires Terns Pharma for $6.7 billion, gaining a novel candidate for chronic myeloid leukemia. This acquisition strengthens Merck's hematology pipeline. Lilly acquires Centessa Pharmaceuticals for $6.3 billion, enhancing its pharmaceutical portfolio with advanced drug candidates. Lilly's $2 billion acquisition of Kelonia Therapeutics expands its biotechnology reach with innovative gene therapy technologies. Lilly also acquires CrossBridge Bio for $300 million, securing next-generation dual-payload antibody-drug conjugates.
Competitive Pressures Drive Pharma M&A Surge
The pharmaceutical sector faces increased pressure to innovate due to rising competition and patent expirations. Companies seek to diversify and strengthen their pipelines to maintain market positions. Competitors like Pfizer pursue similar oncology and biotechnology assets. Merck and Lilly's aggressive acquisition strategy outpaces Pfizer's recent moves, securing critical assets before competitors can act. Their willingness to pay premium prices reflects the urgency to fill portfolio gaps and gain a competitive edge.
Regulatory and Competitive Risks in Pharma M&A
The Federal Trade Commission may scrutinize these acquisitions for antitrust concerns due to market consolidation. Integration risks exist with Terns Pharma's chronic myeloid leukemia candidate, particularly in aligning research teams. Pfizer may respond with a counter-acquisition or strategic partnership to regain competitive ground. Monitor the pipeline progress of acquired assets in Merck and Lilly's Q3 earnings reports.